Priced like an automaker, sputtering Gilead shares lure value bets
February 06, 2017 at 12:40 PM EST
NEW YORK, Feb 6 (Reuters) - Shares of Gilead Sciences Inc are languishing over concerns about the U.S. biotechnology company's declining hepatitis C drugs and profit outlook, but some value investors sense an opportunity with shares at extremely cheap levels.
